CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $20.58, for a total transaction of $51,450.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Debanjan Ray also recently made the following trade(s):

  • On Wednesday, November 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $50,000.00.
  • On Monday, October 2nd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The stock was sold at an average price of $18.10, for a total transaction of $45,250.00.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down $0.24 on Tuesday, hitting $20.55. 389,015 shares of the company’s stock were exchanged, compared to its average volume of 278,100. CytomX Therapeutics, Inc. has a 1-year low of $10.40 and a 1-year high of $24.67.

Several institutional investors and hedge funds have recently made changes to their positions in CTMX. Legal & General Group Plc increased its position in shares of CytomX Therapeutics by 28.6% during the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 1,434 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in shares of CytomX Therapeutics during the third quarter valued at about $107,000. Cubist Systematic Strategies LLC acquired a new stake in shares of CytomX Therapeutics during the second quarter valued at about $174,000. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics during the first quarter valued at about $190,000. Finally, Voya Investment Management LLC acquired a new stake in shares of CytomX Therapeutics during the second quarter valued at about $203,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Several research firms recently issued reports on CTMX. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a research report on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective for the company. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. Finally, Oppenheimer restated a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $31.88.

WARNING: “Debanjan Ray Sells 2,500 Shares of CytomX Therapeutics, Inc. (CTMX) Stock” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/debanjan-ray-sells-2500-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.